Literature DB >> 8366903

Treatment of Parkinson's disease.

D B Calne1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8366903     DOI： 10.1056/NEJM199309303291408

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

1.  Regulation of the subcellular distribution of m4 muscarinic acetylcholine receptors in striatal neurons in vivo by the cholinergic environment: evidence for regulation of cell surface receptors by endogenous and exogenous stimulation.

Authors:  V Bernard; A I Levey; B Bloch
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

2.  Subcellular redistribution of m2 muscarinic acetylcholine receptors in striatal interneurons in vivo after acute cholinergic stimulation.

Authors:  V Bernard; O Laribi; A I Levey; B Bloch
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

3.  Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.

Authors:  N Arai; M Isaji; M Kojima; E Mizuta; S Kuno
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 5.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

6.  Bioluminescence-driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model.

Authors:  Jessica R Zenchak; Brandon Palmateer; Nicolai Dorka; Tariq M Brown; Lina-Marie Wagner; William E Medendorp; Eric D Petersen; Mansi Prakash; Ute Hochgeschwender
Journal:  J Neurosci Res       Date:  2018-03-25       Impact factor: 4.164

7.  The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease.

Authors:  V Peto; C Jenkinson; R Fitzpatrick; R Greenhall
Journal:  Qual Life Res       Date:  1995-06       Impact factor: 4.147

8.  NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats.

Authors:  John E Kelsey; Stephen D Mague; Reyna S Pijanowski; Ryan C Harris; Nancy W Kleckner; Russell T Matthews
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

9.  Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.

Authors:  H Przuntek; D Welzel; M Gerlach; E Blümner; W Danielczyk; H J Kaiser; P H Kraus; H Letzel; P Riederer; K Uberla
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

10.  Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

Authors:  J Dingemanse; K Jorga; G Zürcher; M Schmitt; G Sedek; M Da Prada; P Van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.